Aldo Badano, MIguel Lago, Elena Sizikova, Jana Delfino, Shuyue Guan, Mark A Anastasio, Berkman Sahiner
{"title":"随机数字人现在正在参加计算机成像试验——生成数字队列的方法和工具","authors":"Aldo Badano, MIguel Lago, Elena Sizikova, Jana Delfino, Shuyue Guan, Mark A Anastasio, Berkman Sahiner","doi":"10.1088/2516-1091/ad04c0","DOIUrl":null,"url":null,"abstract":"Abstract Randomized clinical trials, while often viewed as the highest evidentiary bar by which to judge the quality of a medical intervention, are far from perfect. In silico imaging trials are computational studies that seek to ascertain the performance of a medical device by collecting this information entirely via computer simulations. The benefits of in silico trials for evaluating new technology include significant resource and time savings, minimization of subject risk, the ability to study devices that are not achievable in the physical world, allow for the rapid and effective investigation of new technologies and ensure representation from all relevant subgroups. To conduct in silico trials, digital representations of humans are needed. We review the latest developments in methods and tools for obtaining digital humans for in silico imaging studies. First, we introduce terminology and a classification of digital human models. Second, we survey available methodologies for generating digital humans with healthy status and for generating diseased cases and discuss briefly the role of augmentation methods. Finally, we discuss approaches for sampling digital cohorts and understanding the trade-offs and potential for study bias associated with selecting specific patient distributions.","PeriodicalId":74582,"journal":{"name":"Progress in biomedical engineering (Bristol, England)","volume":null,"pages":null},"PeriodicalIF":5.0000,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"The stochastic digital human is now enrolling for in silico imaging trials – Methods and tools for generating digital cohorts\",\"authors\":\"Aldo Badano, MIguel Lago, Elena Sizikova, Jana Delfino, Shuyue Guan, Mark A Anastasio, Berkman Sahiner\",\"doi\":\"10.1088/2516-1091/ad04c0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Randomized clinical trials, while often viewed as the highest evidentiary bar by which to judge the quality of a medical intervention, are far from perfect. In silico imaging trials are computational studies that seek to ascertain the performance of a medical device by collecting this information entirely via computer simulations. The benefits of in silico trials for evaluating new technology include significant resource and time savings, minimization of subject risk, the ability to study devices that are not achievable in the physical world, allow for the rapid and effective investigation of new technologies and ensure representation from all relevant subgroups. To conduct in silico trials, digital representations of humans are needed. We review the latest developments in methods and tools for obtaining digital humans for in silico imaging studies. First, we introduce terminology and a classification of digital human models. Second, we survey available methodologies for generating digital humans with healthy status and for generating diseased cases and discuss briefly the role of augmentation methods. Finally, we discuss approaches for sampling digital cohorts and understanding the trade-offs and potential for study bias associated with selecting specific patient distributions.\",\"PeriodicalId\":74582,\"journal\":{\"name\":\"Progress in biomedical engineering (Bristol, England)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2023-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in biomedical engineering (Bristol, England)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1088/2516-1091/ad04c0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in biomedical engineering (Bristol, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1088/2516-1091/ad04c0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
The stochastic digital human is now enrolling for in silico imaging trials – Methods and tools for generating digital cohorts
Abstract Randomized clinical trials, while often viewed as the highest evidentiary bar by which to judge the quality of a medical intervention, are far from perfect. In silico imaging trials are computational studies that seek to ascertain the performance of a medical device by collecting this information entirely via computer simulations. The benefits of in silico trials for evaluating new technology include significant resource and time savings, minimization of subject risk, the ability to study devices that are not achievable in the physical world, allow for the rapid and effective investigation of new technologies and ensure representation from all relevant subgroups. To conduct in silico trials, digital representations of humans are needed. We review the latest developments in methods and tools for obtaining digital humans for in silico imaging studies. First, we introduce terminology and a classification of digital human models. Second, we survey available methodologies for generating digital humans with healthy status and for generating diseased cases and discuss briefly the role of augmentation methods. Finally, we discuss approaches for sampling digital cohorts and understanding the trade-offs and potential for study bias associated with selecting specific patient distributions.